Skip to Main Content

After years of rumors, Sana Biotechnology is positioning itself to file for an initial public offering that could give it the largest-ever valuation for a preclinical company in biotech.

The company is looking to raise just $150 million in an initial public offering, according to a registration statement filed with the Securities and Exchange Commission on Wednesday. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!